Assignee
REGENERAN PHARMACEUTICALS INC
US·16 granted patents·56 citations·filing 2018–2022
Top patents by PatentIndex Score
16 records- 0198US11732025B2Anti-VEGF protein compositions and methods for producing the sameREGENERAN PHARMACEUTICALS INC·Filed 2022·Granted Aug 22, 2023·11 cites·30 claims
- 0294US11491237B2Cyclodextrin protein drug conjugatesREGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Nov 8, 2022·6 cites·59 claims
- 0394US11357217B2Humanized universal light chain miceREGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Jun 14, 2022·7 cites·25 claims
- 0493US11117970B2Human antibodies to PD-L1REGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Sep 14, 2021·4 cites·15 claims
- 0588US11167004B2Methods for treating severe atopic dermatitis by administering an IL-4R inhibitorREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted Nov 9, 2021·4 cites·20 claims
- 0685USD961376SPackagingREGENERAN PHARMACEUTICALS INC·Filed 2020·Granted Aug 23, 2022·11 cites·1 claims
- 0785US11359246B2Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitorsREGENERAN PHARMACEUTICALS INC·Filed 2021·Granted Jun 14, 2022·1 cites·29 claims
- 0883US11486864B2Method and system of identifying and quantifying antibody fragmentationREGENERAN PHARMACEUTICALS INC·Filed 2020·Granted Nov 1, 2022·1 cites·18 claims
- 0983US11248044B2Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitorREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted Feb 15, 2022·5 cites·27 claims
- 1079US11064685B2Non-human animal models of retinoschisisREGENERAN PHARMACEUTICALS INC·Filed 2018·Granted Jul 20, 2021·1 cites·29 claims
- 1176US11779633B2Glucagon-like peptide 1 receptor agonists and uses thereofREGENERAN PHARMACEUTICALS INC·Filed 2021·Granted Oct 10, 2023·0 cites·5 claims
- 1276US11319375B2Methods and compositions for treating subjects having rheumatoid arthritisREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted May 3, 2022·1 cites·13 claims
- 1373US11655291B2Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin AREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted May 23, 2023·0 cites·22 claims
- 1471US11603408B2Methods for treating skin infection by administering an IL-4R antagonistREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted Mar 14, 2023·0 cites·17 claims
- 1569USD961377SPackagingREGENERAN PHARMACEUTICALS INC·Filed 2020·Granted Aug 23, 2022·4 cites·1 claims
- 1663US11690362B2Nuclease-mediated repeat expansionREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted Jul 4, 2023·0 cites·47 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →